Sage Journals: Discover world-class research

Abstract

This study, conducted in three separate outpatient health care delivery settings, examined the therapeutic expectations of patients with multiple sclerosis (MS) before they initiated interferon beta-lb therapy, the results of current educational procedures to correct unrealistic expectations, and the relationship between post-education expectations and discontinuing therapy. Ninety-nine consecutive patients were seen in a university based outpatient MS clinic, an academic group practice outpatient MS clinic, or a health maintenance organization outpatient neurology clinic Before the educational sessions, 57% of the patients expressed unrealistically optimistic expectations regarding reduction in attack rate and 34% expressed unrealistically optimistic expectations regarding improvement in functional status. Educational procedures significantly altered unrealistic expectations but the results were sub-optimal since 33% of the patients maintained overly optimistic expectations regarding reduction in attack rate. Post-education unrealistic expectations of improvement in functional status were significantly related to discontinuing therapy within 6 months. Three adverse effects of therapy also were related independently to adherence to treatment depression and flu-like symptoms were related to discontinuing therapy while soreness at injection site was related to continuing therapy.

Keywords

multiple sclerosis interferon beta l-b adherence compliance side effects

Get full access to this article

View all access options for this article.

References

1 Goodkin DE . (1994) Drug profile: Interferon beta-lb. Lancet 344: 57–1060.

2 INFB. MS Study Group. (1993) Interferon beta-l-b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661.

3 INFB. MS Study Group. (1993) Interferon beta-l-b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter randomized double-blind placebo-controlled trial. Neurology 43: 662–667.

4 Neilley LK et al. (1995) Side effect profile of interferon beta 1-b (Betaseron). Neurology 45: A437.

5 Goodkin DE . (1996) Interferon beta treatment for multiple sclerosis: Persisting question. Multiple Sclerosis 1: 321–324.

6 O'Brien MK , Petrie K , Raeburn J. (1992) Adherence to medication regimens: Updating a complex medical issue. Medical Care Review 49: 435–445.

7 Becker MH et al. (1979) Patient perceptions and compliance: Recent studies of the health belief model. Compliance in Health Care. Edited by RB Haynes , DW Taylor , DL Sachett . Baltimore MD: Johns Hopkins University Press.

8 Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis. Ann Neurol 13: 227–231.

9 Mohr DC et al. (1995) Expectations of multiple sclerosis patients initiating Betaseron therapy [abstract]. Neurology 45(suppl 4): 197.

10.

10 Jacobs LD et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis Annals of Neurology, in press.

11.

11 Johnson KP et al. (1995) Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III, multicenter double-blind, placebo-controlled trial. Neurology 45: 1268–1276.

Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment

Abstract

Keywords

Get full access to this article

References